Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size is USD 1.11 Billion in 2026

Europe Knee Osteoarthritis (OA) Injectable Treatments Market (By Product Type: Viscosupplements, Stem Cell Therapy Injections, Botulinum Toxin Injections, Combination Injections, Other Biologic Injections; By Mechanism of Action: Lubrication, Anti-inflammatory, and Regenerative; By Disease Severity: Mild Knee OA, Moderate Knee OA, and Severe Knee OA; By Age Group: 40–60 Years and Above 60 Years; By Duration/Dosing Frequency: Weekly over 3–5 Weeks, Multiple Dose Regimen, Single-Dose Therapy, and Monthly; By End Use: Orthopedic Clinics, Hospitals, Ambulatory Surgical Centers (ASCs), Sports Medicine Clinics, and Research Institutes / Regenerative Medicine Centers) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 662 | Published : 12 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 1.04 Bn

Forecast Year,

USD 1.99 Bn

CAGR, 2026 - 2035

6.70%

Report Coverage

Europe

Download Databook

The europe knee osteoarthritis (OA) injectable treatments market size surpassed USD 1.04 billion in 2025 and is predicted to reach around USD 1.99 billion by 2035, registering a CAGR of 6.7% from 2026 to 2035. The growing prevalence of osteoarthritis and the advancement in the healthcare sector are driving the market.

Europe Knee Osteoarthritis (OA) Injectable Treatments Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 1.04 Billion
Market Size in 2026	USD 1.11 Billion
Market Size by 2035	USD 1.99 Billion
CAGR 2026 to 2035	6.7%
Base Year	2025
Forecast Period	2026 to 2035

Europe knee osteoarthritis (OA) injectable treatments market continues to offer lucrative opportunities for pharmaceutical companies, driven by the rising prevalence of osteoarthritis, especially among aging populations. Ongoing pharmaceutical advancements and an increasing focus on disease-modifying therapies are fueling market growth.

Regulatory authorities, such as the European Medicines Agency, maintain stringent evaluation criteria for drug efficacy, safety, and clinical trial design, which influence product approvals. Viscosupplementation agents are commonly used for symptom management, although their adoption varies across countries due to changing clinical guidelines and reimbursement policies.

Segments	Shares (%)
Viscosupplements	45%
Stem Cell Therapy Injections	25%
Botulinum Toxin Injections	12%
Combination Injections	10%
Other Biologic Injections	8%

Viscosupplements - Injectable treatments that provide joint lubrication to alleviate symptoms of knee OA. Viscosupplements segment dominated with 44% share, driven by the elderly population and the growing preference for non-surgical joint therapies.
Stem Cell Therapy Injections - these injections use stem cells to promote tissue regeneration in knee OA patients. The stem cell therapy injections dominated with 25% share, mainly due to the demand for regenerative alternatives to surgery and pain relief.

Segments	Shares (%)
Lubrication	50%
Anti-inflammatory	2%
Regenerative	22%

Lubrication - Injections that restore synovial fluid to reduce joint friction and improve mobility. The lubrication segment dominated with 50% share due to its proven effectiveness in the management of knee OA symptoms by enhancing joint lubrication.
Anti-inflammatory - Injections that reduce inflammation and pain in knee OA patients. The anti-inflammatory segment held 28% share, serving as a core component for managing symptomatic knee OA.

Segments	Shares (%)
Moderate Knee OA	45%
Severe Knee OA	25%
Mild Knee OA	30%

Moderate Knee OA - More pronounced knee OA with noticeable pain and mobility issues. The moderate knee OA segment dominated with 45% share due to the growing demand for injectable treatments to manage moderate symptoms effectively.
Mild Knee OA - Early stage of knee OA with less severe symptoms. The mild knee OA segment held with 30% share, driven by growing demand for early-stage and non-surgical symptom management.

Segments	Shares (%)
40–60 Years	50%
> 60 years	35%

40-60 years - The most common age group for knee OA is with moderate severity and increased symptoms. The 40-60 years segment dominated with 45% share due to the rising incidence of knee OA and the increasing demand for injectable treatments in this group.
>60 years - Older individuals who commonly experience more severe knee OA. This segment held 40% share, as nearly 21% of the European population aged 65 or older and therefore a higher prevalence of knee OA.

Segments	Shares (%)
Weekly over 3–5 weeks	15%
Multiple dose regimen	50%
Single-Dose Therapy	25%
Monthly	10%

Multiple Dose Regimen - Ongoing injections to give continuous symptom relief. The multiple dose regimen dominated with 50% share due to the demand for prolonged symptom management in moderate to severe cases of knee OA.
Single-Dose Therapy - A one-time injection gives relief from knee OA symptoms. The single-dose therapy segment held 25% share mainly due to convenience, reduced clinic visits, and superior clinical outcomes.

Segments	Shares (%)
Orthopedic clinics	25%
Hospitals	40%
Ambulatory Surgical Centers (ASCs)	15%
Sports Medicine Clinics	11%
Research Institutes / Regenerative Medicine Centers	9%

Hospitals - hospitals are medical facilities offering comprehensive care for knee OA patients. The hospitals segment dominated with 40% share due to the important role of hospitals in offering advanced treatments and in the management of complex cases.
Orthopedic clinics - Specialized clinics offering treatments for musculoskeletal conditions. The orthopedic clinics segment held 25% share due to growing demand for outpatient, non-surgical, and same-day joint pain treatments.

Top Companies in the Europe Knee Osteoarthritis (OA) Injectable Treatments Market

Alcon, Inc.
Allergan plc
Anika Therapeutics, Inc.
Arthrex, Inc.
Bioventus, Inc.
Ferring Pharmaceuticals Inc.
Fidia Farmaceutici S.p.A.
Flexion Therapeutics, Inc.
Galderma S.A.
Hyaltech Ltd.
Landec Corporation (LifeCore Biomedical, Inc.)
Meiji Seika Pharma Ltd.
Merz Pharmaceuticals GmbH (Merz Aesthetics, Inc.)
OrthogenRx, Inc.
Roche Holding AG (F. Hoffmann-La Roche AG)
Royal Biologics
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zimmer Biomet

Segments Covered in the Report

By Product Type

Viscosupplements
Stem Cell Therapy Injections
Botulinum Toxin Injections
Combination Injections
Other Biologic Injections

By Mechanism of Action

Lubrication
Anti-inflammatory
Regenerative

By Disease Severity

Moderate Knee OA
Severe Knee OA
Mild Knee OA

By Age Group

40–60 Years
60 years

By Duration/Dosing Frequency

Weekly over 3–5 weeks
Multiple dose regimen
Single-Dose Therapy
Monthly

By End Use

Orthopedic clinics
Hospitals
Ambulatory Surgical Centers (ASCs)
Sports Medicine Clinics
Research Institutes / Regenerative Medicine Centers

List of Tables & Figures

List of Tables

Table 1: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Product Type, 2025-2035 (USD Billion)
Table 2: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mechanism of Action, 2025-2035 (USD Billion)
Table 3: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Disease Severity, 2025-2035 (USD Billion)
Table 4: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Age Group, 2025-2035 (USD Billion)
Table 5: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Duration/Dosing Frequency, 2025-2035 (USD Billion)
Table 6: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by End Use, 2025-2035 (USD Billion)
Table 7: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Viscosupplements, 2025-2035 (USD Billion)
Table 8: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Stem Cell Therapy Injections, 2025-2035 (USD Billion)
Table 9: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Botulinum Toxin Injections, 2025-2035 (USD Billion)
Table 10: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Combination Injections, 2025-2035 (USD Billion)
Table 11: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Other Biologic Injections, 2025-2035 (USD Billion)
Table 12: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Lubrication, 2025-2035 (USD Billion)
Table 13: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Anti-inflammatory, 2025-2035 (USD Billion)
Table 14: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Regenerative, 2025-2035 (USD Billion)
Table 15: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Moderate Knee OA, 2025-2035 (USD Billion)
Table 16: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Severe Knee OA, 2025-2035 (USD Billion)
Table 17: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mild Knee OA, 2025-2035 (USD Billion)
Table 18: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 40-60 Years, 2025-2035 (USD Billion)
Table 19: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 60 Years, 2025-2035 (USD Billion)
Table 20: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Weekly over 3-5 Weeks, 2025-2035 (USD Billion)
Table 21: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Multiple Dose Regimen, 2025-2035 (USD Billion)
Table 22: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Single-Dose Therapy, 2025-2035 (USD Billion)
Table 23: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Monthly, 2025-2035 (USD Billion)
Table 24: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Orthopedic Clinics, 2025-2035 (USD Billion)
Table 25: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Hospitals, 2025-2035 (USD Billion)
Table 26: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Ambulatory Surgical Centers (ASCs), 2025-2035 (USD Billion)
Table 27: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Sports Medicine Clinics, 2025-2035 (USD Billion)
Table 28: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Research Institutes / Regenerative Medicine Centers, 2025-2035 (USD Billion)

List of Figures

Figure 1: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Product Type, 2025 (%)
Figure 2: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Mechanism of Action, 2025 (%)
Figure 3: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Disease Severity, 2025 (%)
Figure 4: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Age Group, 2025 (%)
Figure 5: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Duration/Dosing Frequency, 2025 (%)
Figure 6: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Share, by End Use, 2025 (%)
Figure 7: Europe Knee Osteoarthritis (OA) Injectable Treatments Market Forecast, 2025-2035 (USD Billion)
Figure 8: Viscosupplements Segment Market Forecast, 2025-2035 (USD Billion)
Figure 9: Stem Cell Therapy Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 10: Botulinum Toxin Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 11: Combination Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 12: Other Biologic Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 13: Lubrication Segment Market Forecast, 2025-2035 (USD Billion)
Figure 14: Anti-inflammatory Segment Market Forecast, 2025-2035 (USD Billion)
Figure 15: Regenerative Segment Market Forecast, 2025-2035 (USD Billion)
Figure 16: Moderate Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 17: Severe Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 18: Mild Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 19: 40-60 Years Segment Market Forecast, 2025-2035 (USD Billion)
Figure 20: 60 Years Segment Market Forecast, 2025-2035 (USD Billion)
Figure 21: Weekly over 3-5 Weeks Segment Market Forecast, 2025-2035 (USD Billion)
Figure 22: Multiple Dose Regimen Segment Market Forecast, 2025-2035 (USD Billion)
Figure 23: Single-Dose Therapy Segment Market Forecast, 2025-2035 (USD Billion)
Figure 24: Monthly Segment Market Forecast, 2025-2035 (USD Billion)
Figure 25: Orthopedic Clinics Segment Market Forecast, 2025-2035 (USD Billion)
Figure 26: Hospitals Segment Market Forecast, 2025-2035 (USD Billion)
Figure 27: Ambulatory Surgical Centers (ASCs) Segment Market Forecast, 2025-2035 (USD Billion)
Figure 28: Sports Medicine Clinics Segment Market Forecast, 2025-2035 (USD Billion)
Figure 29: Research Institutes / Regenerative Medicine Centers Segment Market Forecast, 2025-2035 (USD Billion)

Research Methodology

Related Databooks

March 2026